Efficacy and safety of 3 doses of S 47445 versus placebo in patients with Alzheimer's disease at mild to moderate stages with depressive symptoms. A 24-week international, multi-centre, randomized, double-blind, placebo-controlled phase II study in monotherapy followed by an optional 28-week extension period in co-administration with donepezil.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs S 47445 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors IRIS
- 27 Sep 2017 This trial has been completed in Germany (end date: 20 Sep 2017).
- 27 Jul 2017 This trial has been dicontinued in Germany (End date:2017-06-20)
- 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017